ICU · Respiratory
Acute respiratory distress syndrome: phenotyping and personalised ventilation
Also known as ARDS phenotypes · Personalised ventilation · Hyperinflammatory vs hypoinflammatory ARDS · Recruitment manoeuvres · Driving pressure · ARDS subphenotypes · Latent class analysis ARDS · Precision medicine ARDS · Focal vs non-focal ARDS · Direct vs indirect lung injury · Recruitable lung
ARDS is not a single disease — two distinct phenotypes have been identified. Hyperinflammatory ARDS (high inflammatory markers, vasopressor-dependent, lower mortality with higher PEEP): responds better to higher PEEP and prone positioning. Hypoinflammatory ARDS (lower inflammatory markers, more extrapulmonary cause): may not benefit from aggressive PEEP. Personalised ventilation: individualise PEEP based on recruitability (PEEP titration by P-V curves, EIT, oesophageal pressure), driving pressure (<15 cmH2O — Amato meta-analysis: driving pressure is the strongest predictor of mortality), and lung morphology (focal vs non-focal on CT — focal ARDS tolerates higher PEEP poorly). Recruitment manoeuvres controversial (ART trial: caused harm). Prone positioning beneficial for moderate-severe ARDS (PaO2/FiO2 <150). Latent class analysis of the ALVEOLI and FACTT trials (Calfee 2014) identified the hyperinflammatory (type 2) and hypoinflammatory (type 1) subphenotypes using biomarkers — IL-6, IL-8, soluble TNF receptor-1, angiopoietin-2, bicarbonate, protein C. The subphenotype determines treatment response: higher PEEP and simvastatin benefit the hyperinflammatory phenotype but may harm the hypoinflammatory phenotype (HARP-2 secondary analysis, Calfee 2018). Precision medicine in ARDS is evolving but not yet routine bedside practice.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Driving pressure >15 cmH2O is the strongest ventilator-related predictor of mortality
- Recruitment manoeuvres can cause harm (ART trial: increased mortality) — use cautiously
- Focal ARDS (consolidation in dependent lung only) does NOT tolerate high PEEP — worsens overdistension of healthy lung
- Two ARDS phenotypes (hyper/hypoinflammatory) respond differently to PEEP, prone, and fluids
- Higher PEEP benefits the hyperinflammatory subphenotype but may INCREASE mortality in the hypoinflammatory subphenotype
- Simvastatin reduced mortality in the hyperinflammatory HARP-2 subphenotype but showed a harm signal in the hypoinflammatory subphenotype
Overview & definition
The Berlin definition (Ranieri, JAMA 2012) classifies ARDS by timing (within one week of a known clinical insult), bilateral opacities not fully explained by effusions, lobar collapse, or nodules, origin of oedema not fully explained by cardiac failure or fluid overload, and hypoxaemia stratified into mild, moderate, and severe by the PaO₂/FiO₂ ratio under standard ventilator settings.[9] The definition deliberately lumps together a heterogeneous group of precipitants — pneumonia, aspiration, sepsis, trauma, pancreatitis, transfusion — under one umbrella. That heterogeneity is the central problem in ARDS: dozens of pharmacological trials (statins, beta-agonists, nitric oxide, keratinocyte growth factor, antioxidants, surfactants, stem cells) have been neutral overall despite sound preclinical rationale. The patients are not the same patient twice.
Phenotyping is the attempt to split that Berlin umbrella into biologically coherent subgroups that differ in prognosis AND in treatment response, so that ventilation, fluid strategy and drugs can be matched to the patient in front of you. Three overlapping phenotyping axes are in active use today: (1) biological subphenotypes identified by latent class analysis (hyper- versus hypoinflammatory); (2) radiographic / morphological phenotypes (focal versus non-focal, recruitable versus non-recruitable); and (3) aetiological phenotypes (direct versus indirect lung injury).[1][16][17]
[1]References20ShowHide
- [1]Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials Lancet Respir Med, 2014.PMID 24853585
- [2]Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome N Engl J Med, 2015.PMID 25693014
- [3]Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy Am J Respir Crit Care Med, 2017.PMID 27513822
- [4]Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial Lancet Respir Med, 2018.PMID 30078618
- [5]Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study Intensive Care Med, 2018.PMID 30291376
- [6]Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS; ARDS Network. Stability of ARDS subphenotypes over time in two randomised controlled trials Thorax, 2018.PMID 29477989
- [7]McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome N Engl J Med, 2014.PMID 25268516
- [8]Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome N Engl J Med, 2014.PMID 24835849
- [9]Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition JAMA, 2012.PMID 22797452
- [10]Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome N Engl J Med, 2013.PMID 23688302
- [11]Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial JAMA, 2017.PMID 28973363
- [12]Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury N Engl J Med, 2006.PMID 16714767
- [13]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome N Engl J Med, 2010.PMID 20843245
- [14]Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome N Engl J Med, 2019.PMID 31112383
- [15]Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome N Engl J Med, 2018.PMID 29791822
- [16]Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome N Engl J Med, 2006.PMID 16641394
- [17]Pelosi P, D'Onofrio D, Chiumello D, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different Eur Respir J Suppl, 2003.PMID 12946001
- [18]Moore AR, Pienkos SM, Sinha P, et al. Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials Crit Care Med, 2023.PMID 37695136
- [19]Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study Lancet Respir Med, 2020.PMID 32861275
- [20]Guérin C, Papazian L, Reignier J, et al. Effect of driving pressure on mortality in ARDS patients during lung protective mechanical ventilation in two randomized controlled trials Crit Care, 2016.PMID 27894328